Lexeo Therapeutics

Lexeo Therapeutics

  • Founded: 2018
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Batten disease (ODD)
  • Drug types: GEN, NEU, CVV, RAR
  • Lead product: LX1004
  • Product link: https://www.lexeotx.com/pipeline/
  • Funding: $100M Sep 2021; $85M A Jan 2021


lexeotx.com

linkedin.com

job board


Short description:

Gene Therapy

Drug notes:

LX2006 Clin1/Clin2 cardiac Friedreich's ataxia; LX1001 Clin1/Clin2 Alzheimer's; LX2020 Clin0 arrhythmogenic cardiomyopathy; LX1021 RD Alzheimer's; LX2021 RD arrhythmogenic cardiomyopathy; LX2022 RD hypertrophic cardiomyopathy; LX1020 Clin0 Alzheimer's

Long description:

Contact us to add description.

Jobs:


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com